Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CONGESTIVE HEART FAILURE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED METHOD
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CONGESTIVE HEART FAILURE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMSUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.1.1 PREVALENCE OF CONGESTIVE HEART FAILURE
5.1.1.1. INCEDENCE OF CONGESTIVE HEART FAILURE TREATED BY SURGERY
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH NEUROLOGIST
6.8 INTERVIEWS WITH PHYSICAL THERAPIST
6.9 INTERVIEWS WITH GENETICS SPECIALIST
6.1 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL CONGESTIVE HEART FAILURE MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATIONS
11.2.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
11.2.1.1. ENALAPRRIL
11.2.1.1.1. MARKET VALUE (USD MN)
11.2.1.1.2. MARKET VOLUME (SU)
11.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.2. LISINOPRIL
11.2.1.2.1. MARKET VALUE (USD MN)
11.2.1.2.2. MARKET VOLUME (SU)
11.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.3. CAPTOPRIL
11.2.1.3.1. MARKET VALUE (USD MN)
11.2.1.3.2. MARKET VOLUME (SU)
11.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.4. OTHERS
11.2.2 ANGIOTENSIN II RECEPTOR BLOCKERS
11.2.2.1. LOSARTAN
11.2.2.1.1. MARKET VALUE (USD MN)
11.2.2.1.2. MARKET VOLUME (SU)
11.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.2.2. VALSARTAN
11.2.2.2.1. MARKET VALUE (USD MN)
11.2.2.2.2. MARKET VOLUME (SU)
11.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.2.3. CANDESARTAN
11.2.2.3.1. MARKET VALUE (USD MN)
11.2.2.3.2. MARKET VOLUME (SU)
11.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.2.4. OTHERS
11.2.3 BETA BLOCKERS
11.2.3.1. CARVEDILOL
11.2.3.1.1. MARKET VALUE (USD MN)
11.2.3.1.2. MARKET VOLUME (SU)
11.2.3.1.3. AVERAGE SELLING PRICE (USD)
11.2.3.2. METOPROLOL
11.2.3.2.1. MARKET VALUE (USD MN)
11.2.3.2.2. MARKET VOLUME (SU)
11.2.3.2.3. AVERAGE SELLING PRICE (USD)
11.2.3.3. BISPROLOL
11.2.3.3.1. MARKET VALUE (USD MN)
11.2.3.3.2. MARKET VOLUME (SU)
11.2.3.3.3. AVERAGE SELLING PRICE (USD)
11.2.3.4. OTHERS
11.2.4 DIURETICS
11.2.4.1. FUROSEMIDE
11.2.4.1.1. MARKET VALUE (USD MN)
11.2.4.1.2. MARKET VOLUME (SU)
11.2.4.1.3. AVERAGE SELLING PRICE (USD)
11.2.4.2. OTHERS
11.2.5 ALDOSTERONE ANTAGONIST
11.2.5.1. SPIRONOLACTONE
11.2.5.1.1. MARKET VALUE (USD MN)
11.2.5.1.2. MARKET VOLUME (SU)
11.2.5.1.3. AVERAGE SELLING PRICE (USD)
11.2.5.2. EPLERENONE
11.2.5.2.1. MARKET VALUE (USD MN)
11.2.5.2.2. MARKET VOLUME (SU)
11.2.5.2.3. AVERAGE SELLING PRICE (USD)
11.2.5.3. OTHERS
11.2.6 DIGOXIN
11.2.6.1. MARKET VALUE (USD MN)
11.2.6.2. MARKET VOLUME (SU)
11.2.6.3. AVERAGE SELLING PRICE (USD)
11.2.7 VERICIGUAT (VERQUVO)
11.2.7.1. MARKET VALUE (USD MN)
11.2.7.2. MARKET VOLUME (SU)
11.2.7.3. AVERAGE SELLING PRICE (USD)
11.2.8 POSITIVE INOTROPES
11.2.8.1. MARKET VALUE (USD MN)
11.2.8.2. MARKET VOLUME (SU)
11.2.8.3. AVERAGE SELLING PRICE (USD)
11.2.9 COMBINATION DRUGS
11.2.9.1. HYDRALAZINE AND ISOSORBIDE DINITRATE (BIDIL)
11.2.9.1.1. MARKET VALUE (USD MN)
11.2.9.1.2. MARKET VOLUME (SU)
11.2.9.1.3. AVERAGE SELLING PRICE (USD)
11.2.9.2. OTHERS
11.3 DEVICES
11.3.1 PACEMAKER
11.3.1.1. SINGLE CHAMBER PACEMAKER
11.3.1.1.1. MRI COMPATIBLE PACEMAKER
11.3.1.1.2. CONVENTIONAL PACEMAKER
11.3.1.2. DUAL-CHAMBER PACEMAKER
11.3.1.2.1. MRI COMPATIBLE PACEMAKER
11.3.1.2.2. CONVENTIONAL PACEMAKER
11.3.1.3. BIVENTRICULAR/CRT PACEMAKER
11.3.1.3.1. MRI COMPATIBLE PACEMAKER
11.3.1.3.2. CONVENTIONAL PACEMAKER
11.3.2 CARDIAC RESYNCHONIZATION THERAPY
11.3.2.1. CARDIAC RESYNCHRONIZATION THERAPY PACEMAKER (CRT-P)
11.3.2.1.1. MRI COMPATIBLE CRT-P DEVICES
11.3.2.1.1.1 MARKET VALUE (USD MN)
11.3.2.1.1.2 MARKET VOLUME (UNITS)
11.3.2.1.1.3 AVERAGE SELLING PRICE (USD)
11.3.2.1.2. CONVENTIONAL CRT-P DEVICES
11.3.2.1.2.1 MARKET VALUE (USD MN)
11.3.2.1.2.2 MARKET VOLUME (UNITS)
11.3.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.2. CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D)
11.3.2.2.1. MRI COMPATIBLE CRT-D DEVICES
11.3.2.2.1.1 MARKET VALUE (USD MN)
11.3.2.2.1.2 MARKET VOLUME (UNITS)
11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.2. CONVENTIONAL CRT-D DEVICES
11.3.2.2.2.1 MARKET VALUE (USD MN)
11.3.2.2.2.2 MARKET VOLUME (UNITS)
11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.3.3 IMPLANTABLE CARDIOVERTER DEFIBRILATORS
11.3.3.1. TRANSVENOUS IMPLANTABLE CARDIOVERTER-DEFIBRILATOR
11.3.3.1.1. MARKET VALUE (USD MN)
11.3.3.1.2. MARKET VOLUME (UNITS)
11.3.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.3.2. SUBCUTANEOUS IMPNATABLE CARDIO DEFIBRILLATORS
11.3.3.2.1. MARKET VALUE (USD MN)
11.3.3.2.2. MARKET VOLUME (UNITS)
11.3.3.2.3. AVERAGE SELLING PRICE (USD)
11.3.3.3. OTHERS
11.3.4 VENTRICULAR ASSIST DEVICES
11.3.4.1. MARKET VALUE (USD MN)
11.3.4.2. MARKET VOLUME (UNITS)
11.3.4.3. AVERAGE SELLING PRICE (USD)
11.4 SURGERY
11.5 OTHERS
12 GLOBAL CONGESTIVE HEART FAILURE MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 PILL
12.2.2 CAPSULE
12.2.3 TABLETS
12.2.4 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 INTRAMUSCULAR
12.4 OTHERS
13 GLOBAL CONGESTIVE HEART FAILURE MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.2.1 LONG TERM CARE HOSPITALS
13.2.2 ACUTE CARE HOSPITALS
13.2.3 NURSING FACILITIES
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 GLOBAL CONGESTIVE HEART FAILURE MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITALS PHARMACY
14.4 RETAIL PHARMACY
14.5 ONLINE PHARMACY
14.6 OTHERS
15 GLOBAL CONGESTIVE HEART FAILURE MARKET, BY GEOGRAPHY
GLOBAL CONGESTIVE HEART FAILURE MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.1.1. U.S. CONGESTIVE HEART FAILURE MARKET, BY TREATMENT
15.1.1.2. U.S. CONGESTIVE HEART FAILURE MARKET, BY ROUTE OF ADMINISTRATION
15.1.1.3. U.S. CONGESTIVE HEART FAILURE MARKET, BY END USER
15.1.1.4. U.S. CONGESTIVE HEART FAILURE MARKET, BY DISTRIBUTION CHANNEL
15.1.2 CANADA
15.1.3 MEXICO
15.1.4 DOMINICAN REPUBLIC
15.1.5 JAMAICA
15.1.6 PANAMA
15.2 EUROPE
15.2.1 GERMANY
15.2.2 FRANCE
15.2.3 U.K.
15.2.4 HUNGARY
15.2.5 LITHUANIA
15.2.6 AUSTRIA
15.2.7 IRELAND
15.2.8 NORWAY
15.2.9 POLAND
15.2.10 ITALY
15.2.11 SPAIN
15.2.12 RUSSIA
15.2.13 TURKEY
15.2.14 NETHERLANDS
15.2.15 SWITZERLAND
15.2.16 REST OF EUROPE
15.3 ASIA-PACIFIC
15.3.1 JAPAN
15.3.2 CHINA
15.3.3 TAIWAN
15.3.4 SOUTH KOREA
15.3.5 INDIA
15.3.6 AUSTRALIA
15.3.7 SINGAPORE
15.3.8 THAILAND
15.3.9 MALAYSIA
15.3.10 INDONESIA
15.3.11 PHILIPPINES
15.3.12 VIETNAM
15.3.13 REST OF ASIA-PACIFIC
15.4 SOUTH AMERICA
15.4.1 BRAZIL
15.4.2 ECUADOR
15.4.3 CHILE
15.4.4 COLOMBIA
15.4.5 VENEZUELA
15.4.6 ARGENTINA
15.4.7 PERU
15.4.8 CURAÇAO
15.4.9 PARAGUAY
15.4.10 URUGUAY
15.4.11 TRINIDAD AND TOBAGO
15.4.12 REST OF SOUTH AMERICA
15.5 MIDDLE EAST AND AFRICA
15.5.1 SOUTH AFRICA
15.5.2 SAUDI ARABIA
15.5.3 UAE
15.5.4 EGYPT
15.5.5 KUWAIT
15.5.6 ISRAEL
15.5.7 BOLIVIA
15.5.8 REST OF MIDDLE EAST AND AFRICA
15.5.9 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16 GLOBAL CONGESTIVE HEART FAILURE MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL CONGESTIVE HEART FAILURE MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL CONGESTIVE HEART FAILURE MARKET, COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPEMENTS
18.2 NOVARTIS AG
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPEMENTS
18.3 GENENTECH, INC.
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPEMENTS
18.4 BAYER AG
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPEMENTS
18.5 JANSSEN GLOBAL SERVICES, LLC
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPEMENTS
18.6 CELGENE CORPORATION
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPEMENTS
18.7 AMGEN INC.
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPEMENTS
18.8 ELI LILLY AND COMAPNY
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPEMENTS
18.9 MERCK & CO.
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPEMENTS
18.1 ABBVIE INC.
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPEMENTS
18.11 TEVA PHARMACEUTICALS
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPEMENTS
18.12 DR REDDY LABORATORIES
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPEMENTS
18.13 SUN PHARMACEUTICALS
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPEMENTS
18.14 MEDTRONIC
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPEMENTS
18.15 ABBOTT
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPEMENTS
18.16 BOSTON SCIENTIFIC
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPEMENTS
18.17 ABIOMED INC
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPEMENTS
18.18 BERLIN HEART
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPEMENTS
18.19 BIOTRONIK SE
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPEMENTS
18.2 JARVIK HEART INC
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPEMENTS
18.21 LEPU MEDICAL
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPEMENTS
18.22 MICROPORT SCIENTIFIC CORPORATION
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPEMENTS
18.23 STRYKER
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPEMENTS
18.24 KONINKLIJKE PHILIPS N.V
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPEMENTS
18.25 BIOTRINIK
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPEMENTS
18.26 MINDRAY MEDICAL INTERNATIONAL LTD
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPEMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
